Predictors of annual pharmaceutical costs in australia for community-based individuals with, or at risk of, cardiovascular disease: Analysis of australian data from the reach registry

American Journal of Cardiovascular Drugs

Volumn 10, Issue 2, 2010, Pages 85-94

  Ademi, Zanfina ^a   Liew, Danny ^b   Hollingsworth, Bruce ^c   Steg, Ph Gabriel ^d   Bhatt, Deepak L ^e   Reid, Christopher M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d INSERM   (France)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; METHYLDOPA; NICOTINIC ACID; NITRATE; PRAZOSIN; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DRUG COST; DYSLIPIDEMIA; FEMALE; GROUPS BY AGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SEX DIFFERENCE; VASCULAR DISEASE;

EID: 77950184794     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11530670-000000000-00000     Document Type: Article

References (39)

1. World health report. Geneva: World Health Organisation, 2008
2. Begg S, Vos T, Barker B, et al. The burden of disease and injury in Australia 2003 [AIHW cat. no.: PHE 82]. Canberra (ACT): AIHW, 2007
3. American Heart Association. Heart disease and stroke statistics: 2007 update. Dallas (TX): American Heart Association, 2007
4. Access Economics. The shifting burden of cardiovascular disease in Australia: NationalHeart Foundation of Australia, 2005 [online]. Available from URL: http://www.heartfoundation.org.au/SiteCollectionDocuments/cvd%20shifting %20burden.pdf [Accessed 2009 Feb 1]
5. Medicare Australia. Pharmaceutical Benefits Schedule item reports: period September 2006 to September 2007 [online]. Available from URL: https:// www.medicareaustralia.gov.au/statistics/pbs-item.shtml [Accessed 2009 Feb 1]
6. Thompson D, Wolf AM. The medical-care cost burden of obesity. Obes Rev 2001; 2 (3): 189-197
7. Trogdon JG, Finkelstein EA, Hylands T, et al. Indirect costs of obesity: a review of the current literature. Obes Rev 2008; 9 (5): 489-500
8. Quesenberry Jr CP, Caan B, Jacobson A. Obesity, health services use, and health care costs amongmembers of a healthmaintenance organization. Arch Intern Med 1998; 158 (5): 466-472
9. Oliva J, Lobo F, Molina B, et al. Direct health care costs of diabetic patients in Spain. Diabetes Care 2004; 27 (11): 2616-2621
10. Nichols GA, Brown JB.Higher medical care costs accompany impaired fasting glucose. Diabetes Care 2005; 28 (9): 2223-2229
11. Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment. The SOS Intervention Study. Arch Intern Med 2002; 162 (18): 2061-2069
12. McCormick I, Stone I. Economic costs of obesity and the case for government intervention. Obes Rev 2006; 8 Suppl. 1: 161-164
13. Matsuda KO, Kuriyama S, HozawaA, et al. The joint impact of cardiovascular risk factors upon medical costs. Prevent Med 2007; 44: 349-355
14. Lloyd A, Schmieder C, MarchantN. Financial and health costs of uncontrolled blood pressure in the United Kingdom. Pharmacoeconomics 2003; 21 Suppl. 1: 33-41
15. Kuriyama S, Hozawa A, OhmoriK, et al. Joint impact of health risks on health care charges: 7-year follow-up of National Health Insurance beneficiaries in Japan (the Ohsaki Study). Prevent Med 2004; 39: 1194-1199
16. Degli Esposti L, Valpiani G. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics 2004; 22 (14): 907-928
17. Raebel MA, Malone DC, Conner DA, et al. Health services use and health care costs of obese and nonobese individuals. Arch Intern Med 2004; 164 (19): 2135-2140
18. Finkelstein EA, Brown JB, Trogdon JG, et al. Age specific impact of obesity on prevalence and costs of diabetes and dyslipidemia. Value Health 2007; 10 Suppl. 1: S45-51
19. Hay J. The cost effectiveness of cardiovascular medicines. Curr Atheroscl Rep 2005; 7 (2): 79-80
20. Linjer E, Hedner T, Jonsson B, et al. Cost analysis of different pharmacological treatment strategies in elderly hypertensives. Blood Pressure 2005; 14 (2): 107-113
21. Bramkamp M, Radovanovic D, Erne P, et al. Determinants of costs and the length of stay in acute coronary syndromes: a real life analysis of more than 10,000 patients. Cardiovasc Drugs Ther 2007; 21 (5): 389-398
22. Chapko M, Liu C, Perkins M, et al. Equivalence of two healthcare costing methods: bottom-up and top-down. Health Econ 2009; 18 (10): 1188-1201
23. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295 (2): 180-189
24. Ohman EM, Bhatt DL, Steg PG, et al. The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events. Study design. Am Heart J 2006; 151 (4): 786 e1-10
25. Reid C, Nelson MR, Shiel L, et al. Australians at risk: management of cardiovascular risk factors in the REACH Registry.Heart Lung Circ 2008; 17 (2): 114-118
26. Department of Health and Ageing. Schedule of Pharmaceutical Benefits for approved pharmacists and medical practitioners, 2007 [online]. Available from URL: http://www.pbs.gov.au/html/healthpro/publication/view?date= 20070901&type=FlashPaper&name=general-schedule [Accessed 2008 Oct 10]
27. National Heart Foundation of Australia, the Cardiac Society of Australia and New Zealand. Reducing risk in heart disease, 2007 (updated 2008) [online]. Available from URL: http://www.heartfoundation.org.au/SiteCollectionDocuments/ A%20RR%20RRIHD%202008Update%20Guideline%20pdf.pdf [Accessed 2008 Nov 10]
28. Smith SJ, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113 (9): 2363-2372
29. Salman H, Bergman M, Hart J, et al. The effect of drug cost on hypertension treatment decision. Public Health 1999; 113 (5): 243-246
30. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [NIH publication report no.: 02-5215]. Bethesda (MD): National Institute of Health, National Heart, Lung, and Blood Institute, 2002 Sep
31. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004-2006. Med J Aust 2008; 188 (4): 224-227
32. Cutler DM, Long G, Berndt ER, et al. The value of antihypertensive drugs: a perspective on medical innovation. Health Aff 2007; 26 (1): 97-110
33. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898
34. Rickard M. How much will the PBS cost? Projected trends in commonwealth expenditure. Parliamentary Library, Social Policy Group. Research note no.29 2003-2004 [online]. Available from URL: http://www.aph.gov.au/library/ Pubs/RN/2003-04/04rn29.htm [Accessed 2008 Dec 9]
35. Mahoney EM, Wang K, Cohen DJ, et al. One-year costs in patients with history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes 2008; 1: 38-45
36. Senes S, Penm E. Australian Institute of Health and Welfare. Medicines for cardiovascular health: are they used appropriately? Cardiovascular disease series no.27 [AIHW cat. no.: 36]. Canberra (ACT): AIHW, 2007
37. Top 10 drugs. Australian Prescriber [online]. Available from URL: http:// www.australianprescriber.com/magazine/31/6/artid/992/ [Accessed 2008Dec 12]
38. Access Economics 2006. The economic costs of obesity: report to Diabetes Australia [online]. Available from URL: http://www.accesseconomics.com. au/publicationsreports/reports.php [Accessed 2008 Dec 12]
39. Harris A. Chronic disease and labour force participation in Australia: an endogenous multivariate probit analysis of clinical prevalence data.Melbourne (VIC): Centre for Health Economics, 2008 Feb: 1-18